Literature DB >> 25006192

Recommended patient-reported core set of symptoms to measure in prostate cancer treatment trials.

Ronald C Chen1, Peter Chang2, Richard J Vetter2, Himansu Lukka2, William A Stokes2, Martin G Sanda2, Deborah Watkins-Bruner2, Bryce B Reeve2, Howard M Sandler2.   

Abstract

The National Cancer Institute (NCI) Symptom Management and Health-Related Quality of Life Steering Committee convened four working groups to recommend core sets of patient-reported outcomes to be routinely incorporated in clinical trials. The Prostate Cancer Working Group included physicians, researchers, and a patient advocate. The group's process included 1) a systematic literature review to determine the prevalence and severity of symptoms, 2) a multistakeholder meeting sponsored by the NCI to review the evidence and build consensus, and 3) a postmeeting expert panel synthesis of findings to finalize recommendations. Five domains were recommended for localized prostate cancer: urinary incontinence, urinary obstruction and irritation, bowel-related symptoms, sexual dysfunction, and hormonal symptoms. Four domains were recommended for advanced prostate cancer: pain, fatigue, mental well-being, and physical well-being. Additional domains for consideration include decisional regret, satisfaction with care, and anxiety related to prostate cancer. These recommendations have been endorsed by the NCI for implementation.
© The Author 2014. Published by Oxford University Press. All rights reserved.

Entities:  

Mesh:

Year:  2014        PMID: 25006192      PMCID: PMC4192044          DOI: 10.1093/jnci/dju132

Source DB:  PubMed          Journal:  J Natl Cancer Inst        ISSN: 0027-8874            Impact factor:   13.506


  99 in total

Review 1.  Issues and challenges with integrating patient-reported outcomes in clinical trials supported by the National Cancer Institute-sponsored clinical trials networks.

Authors:  Deborah Watkins Bruner; Charlene J Bryan; Neil Aaronson; C Craig Blackmore; Michael Brundage; David Cella; Patricia A Ganz; Carolyn Gotay; Pamela S Hinds; Alice B Kornblith; Benjamin Movsas; Jeff Sloan; Lari Wenzel; Giles Whalen
Journal:  J Clin Oncol       Date:  2007-11-10       Impact factor: 44.544

2.  Randomized clinical trial of a family intervention for prostate cancer patients and their spouses.

Authors:  Laurel L Northouse; Darlene W Mood; Ann Schafenacker; James E Montie; Howard M Sandler; Jeffrey D Forman; Maha Hussain; Kenneth J Pienta; David C Smith; Trace Kershaw
Journal:  Cancer       Date:  2007-12-15       Impact factor: 6.860

3.  The impact of treatment choice for localized prostate cancer on response to phosphodiesterase inhibitors.

Authors:  Irwin H Lee; Natalia Sadetsky; Peter R Carroll; Howard M Sandler
Journal:  J Urol       Date:  2008-01-18       Impact factor: 7.450

4.  Insurance and quality of life in men with prostate cancer: data from the Cancer of the Prostate Strategic Urological Research Endeavor.

Authors:  Natalia Sadetsky; Deborah P Lubeck; David J Pasta; David M Latini; Janeen DuChane; Peter R Carroll
Journal:  BJU Int       Date:  2008-03       Impact factor: 5.588

5.  Health-related quality of life results in pathologic stage C prostate cancer from a Southwest Oncology Group trial comparing radical prostatectomy alone with radical prostatectomy plus radiation therapy.

Authors:  Carol M Moinpour; Katherine A Hayden; Joseph M Unger; Ian M Thompson; Mary W Redman; Edith D Canby-Hagino; Betsy A Higgins; Jerry W Sullivan; Dianne Lemmon; Sheila Breslin; E David Crawford
Journal:  J Clin Oncol       Date:  2008-01-01       Impact factor: 44.544

6.  Impact of nerve sparing technique on patient self-assessed outcomes after radical perineal prostatectomy.

Authors:  Hubert R Kübler; Timothy Y Tseng; Leon Sun; Johannes Vieweg; Michael J Harris; Philipp Dahm
Journal:  J Urol       Date:  2007-06-11       Impact factor: 7.450

7.  Quality of life in young men after radical prostatectomy.

Authors:  J L Wright; D W Lin; J E Cowan; P R Carroll; M S Litwin
Journal:  Prostate Cancer Prostatic Dis       Date:  2007-05-22       Impact factor: 5.554

8.  Effects of skeletal morbidities on longitudinal patient-reported outcomes and survival in patients with metastatic prostate cancer.

Authors:  Venita DePuy; Kevin J Anstrom; Liana D Castel; Kevin A Schulman; Kevin P Weinfurt; Fred Saad
Journal:  Support Care Cancer       Date:  2007-07       Impact factor: 3.359

9.  Psychometric properties of a prostate cancer radiation late toxicity questionnaire.

Authors:  George Rodrigues; Glenn Bauman; Michael Lock; David D'Souza; Jeff Mahon
Journal:  Health Qual Life Outcomes       Date:  2007-05-31       Impact factor: 3.186

10.  Brief assessment of priority symptoms in hormone refractory prostate cancer: the FACT Advanced Prostate Symptom Index (FAPSI).

Authors:  Susan Yount; David Cella; Donald Banik; Talat Ashraf; Daniel Shevrin
Journal:  Health Qual Life Outcomes       Date:  2003-11-21       Impact factor: 3.186

View more
  35 in total

1.  Trial Design and Objectives for Castration-Resistant Prostate Cancer: Updated Recommendations From the Prostate Cancer Clinical Trials Working Group 3.

Authors:  Howard I Scher; Michael J Morris; Walter M Stadler; Celestia Higano; Ethan Basch; Karim Fizazi; Emmanuel S Antonarakis; Tomasz M Beer; Michael A Carducci; Kim N Chi; Paul G Corn; Johann S de Bono; Robert Dreicer; Daniel J George; Elisabeth I Heath; Maha Hussain; Wm Kevin Kelly; Glenn Liu; Christopher Logothetis; David Nanus; Mark N Stein; Dana E Rathkopf; Susan F Slovin; Charles J Ryan; Oliver Sartor; Eric J Small; Matthew Raymond Smith; Cora N Sternberg; Mary-Ellen Taplin; George Wilding; Peter S Nelson; Lawrence H Schwartz; Susan Halabi; Philip W Kantoff; Andrew J Armstrong
Journal:  J Clin Oncol       Date:  2016-02-22       Impact factor: 44.544

2.  Performance Measures Based on How Adults With Cancer Feel and Function: Stakeholder Recommendations and Feasibility Testing in Six Cancer Centers.

Authors:  Angela M Stover; Benjamin Y Urick; Allison M Deal; Randall Teal; Maihan B Vu; Jessica Carda-Auten; Jennifer Jansen; Arlene E Chung; Antonia V Bennett; Anne Chiang; Charles Cleeland; Yehuda Deutsch; Edmund Tai; Dylan Zylla; Loretta A Williams; Collette Pitzen; Claire Snyder; Bryce Reeve; Tenbroeck Smith; Kristen McNiff; David Cella; Michael N Neuss; Robert Miller; Thomas M Atkinson; Patricia A Spears; Mary Lou Smith; Cindy Geoghegan; Ethan M Basch
Journal:  JCO Oncol Pract       Date:  2020-02-19

Review 3.  Cancer and lesbian, gay, bisexual, transgender/transsexual, and queer/questioning (LGBTQ) populations.

Authors:  Gwendolyn P Quinn; Julian A Sanchez; Steven K Sutton; Susan T Vadaparampil; Giang T Nguyen; B Lee Green; Peter A Kanetsky; Matthew B Schabath
Journal:  CA Cancer J Clin       Date:  2015-07-17       Impact factor: 508.702

Review 4.  The evolution of brachytherapy for prostate cancer.

Authors:  Nicholas G Zaorsky; Brian J Davis; Paul L Nguyen; Timothy N Showalter; Peter J Hoskin; Yasuo Yoshioka; Gerard C Morton; Eric M Horwitz
Journal:  Nat Rev Urol       Date:  2017-06-30       Impact factor: 14.432

5.  Implementation of Symptom Questionnaires Into Oncology Workflow.

Authors:  Angela M Stover; Ethan M Basch
Journal:  J Oncol Pract       Date:  2016-10       Impact factor: 3.840

Review 6.  Key design and analysis principles for quality of life and patient-reported outcomes in clinical trials.

Authors:  Joseph M Unger; Riha Vaidya; John L Gore
Journal:  Urol Oncol       Date:  2018-03-21       Impact factor: 3.498

Review 7.  Integration of Patient Reported Outcomes in Drug Development in Genitourinary Cancers.

Authors:  Risa L Wong; Alicia K Morgans
Journal:  Curr Oncol Rep       Date:  2020-02-08       Impact factor: 5.075

8.  Caution with Use of the EPIC-50 Urinary Bother Scale: How Voiding Dysfunction Modifies its Performance.

Authors:  Lin Yang; Adam S Kibel; Graham A Colditz; Ratna Pakpahan; Kellie R Imm; Sonya Izadi; Robert L Grubb; Kathleen Y Wolin; Siobhan Sutcliffe
Journal:  J Urol       Date:  2017-07-18       Impact factor: 7.450

9.  Patient-Reported Outcomes after Monitoring, Surgery, or Radiotherapy for Prostate Cancer.

Authors:  J L Donovan; F C Hamdy; J A Lane; D E Neal; M Mason; C Metcalfe; E Walsh; J M Blazeby; T J Peters; P Holding; S Bonnington; T Lennon; L Bradshaw; D Cooper; P Herbert; J Howson; A Jones; N Lyons; E Salter; P Thompson; S Tidball; J Blaikie; C Gray; P Bollina; J Catto; A Doble; A Doherty; D Gillatt; R Kockelbergh; H Kynaston; A Paul; P Powell; S Prescott; D J Rosario; E Rowe; M Davis; E L Turner; R M Martin
Journal:  N Engl J Med       Date:  2016-09-14       Impact factor: 91.245

Review 10.  Patient-reported outcomes in metastatic castration-resistant prostate cancer.

Authors:  Lesley Fallowfield; Heather Payne; Valerie Jenkins
Journal:  Nat Rev Clin Oncol       Date:  2016-06-28       Impact factor: 66.675

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.